The future of RNA-lipid nanoparticles for CAR-T cell therapy development

Thursday 08:00 PST / 11:00 EST / 16:00 GMT / 17:00 CET

Sponsor

The future of RNA-lipid nanoparticles for CAR-T cell therapy development

Live30 webinars are thirty-minute presentations designed toupdate you on the latest innovations, applications, and data in a fast yetinteractive format.

Most clinical-stage and approved CAR-T cell therapies are autologous and utilize viral vectors for transduction of DNA into T cells for persistent expression of CAR. These therapies have shown remarkable clinical outcomes. However, important challenges need to be overcome to make CAR-T cell therapies accessible to a wider patient population, including high manufacturing costs and potential short and long-term toxicities.

As the field looks to develop the next generation of CAR-T cell therapies, there is growing interest in non-viral RNA delivery for new applications that require transient rather than stable expression. In this webinar, we will explore the use of lipid nanoparticles (LNPs) for RNA delivery into T cells to enable the next generation of autologous and allogeneic cell therapies.

Webinar attendees will learn more about:

How RNA-LNPs are being used to generate CAR-T cells
Key applications in T cells where transient expression is advantageous over stable expression
Genome editing of T cells using LNPs
Future of LNPs in autologous and allogeneic cell therapies

Samuel Clarke

Director of R&D at Cytiva

Dr Samuel Clarke is an expert in the development of nanoparticles for research, diagnostic and therapeutic applications with more than 15 years’ experience in the field. Samuel is currently the Director of R&D at Precision NanoSystems (now part of Cytiva) where he is responsible for the development of lipid nanoparticle reagents for genomic medicine applications. He?has a PhD and post-doc from McGill University and École Normale Supérieure.